Q1 2026 SeQuent Scientific Ltd Earnings Call Transcript
Key Points
- Sequent Scientific Ltd (BOM:512529) reported a strong revenue growth of 13.1% year-on-year, reaching INR4,414 million for Q1 FY26.
- The company achieved a 25% growth in pre-ESOP EBITDA, reaching INR602 million with a margin of 13.6%.
- The formulation business, which constitutes 75% of the company's operations, sustained a sales growth of 13% year-on-year.
- The API business showed significant momentum, achieving a 14% year-on-year growth and reaching the INR100-crore mark for the quarter.
- The proposed merger with Viyash Life Sciences is on track, with key regulatory approvals obtained, promising future synergies and growth opportunities.
- The Europe market showed only a 4% year-on-year growth due to a high base effect from the previous year.
- India's formulation business experienced subdued growth of 8% due to seasonality factors affecting the rural economy and disease outbreaks.
- Sequential gross margin showed a drop due to product mix changes, despite a year-on-year improvement.
- The company faces ongoing challenges in maintaining high margins in the API segment due to competitive pressures.
- There is no immediate plan to consolidate the 40% minority interest in the profitable Spanish operations, which could limit full control and potential synergies.
Ladies and gentlemen, good day and welcome to the SeQuent Scientific Limited Q1 FY26 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Abhishek. Thank you, and over to you, sir.
Thank you, Manav. A very good morning to all of you, and thank you for joining us today for SeQuent Scientific's earnings conference call for the first quarter of financial year 2026.
Today, we have with us Mr. Rajaram, MD and CEO of SeQuent Scientific; Dr. Hari Babu, Whole-Time Director and CEO, Viyash Life Sciences; Mr. Saurav Bhala, CFO, SeQuent Scientific; and Mr. Ramakant Singani, CFO, Viyash Life Sciences, to share the highlights of the business and financials for the quarter.
I hope you've gone through our results release and the quarterly Investor presentation, which have been uploaded on our website as well as the stock exchange website. The transcript of this call will be available in a week
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
